Sanofi (SNY): Modelo de negócios Canvas [Jan-2025 Atualizado]

No cenário dinâmico dos produtos farmacêuticos globais, a Sanofi é um farol imponente de inovação e proezas estratégicas, elaborando meticulosamente seu modelo de negócios para revolucionar a prestação de serviços de saúde. Com uma abordagem abrangente que abrange pesquisa de ponta, soluções centradas no paciente e tecnologias médicas transformadoras, o modelo de negócios da Sanofi Canvas revela um projeto sofisticado para navegar no complexo mundo da saúde e desenvolvimento farmacêutico. Mergulhe nos intrincados mecanismos que alimentam essa gigante multinacional de saúde e descubra como a Sanofi transforma a experiência científica em soluções médicas que mudam a vida que tocam milhões de vidas em todo o mundo.

Sanofi (SNY) - Modelo de negócios: Parcerias -chave

Instituições de pesquisa farmacêutica e universidades

A Sanofi colabora com 127 instituições de pesquisa acadêmica globalmente em 2024. As parcerias -chave incluem:

Instituição	Foco na pesquisa	Duração da parceria
Instituto de Tecnologia de Massachusetts	Pesquisa de imunologia	5 anos
Escola de Medicina de Harvard	Terapêutica de doenças raras	3 anos
Universidade de Oxford	Desenvolvimento da vacina	4 anos

Organizações de fabricação contratadas

A Sanofi trabalha com 42 organizações de fabricação de contratos em todo o mundo.

• Investimento total em parceria de fabricação: € 1,2 bilhão em 2024
• Distribuição geográfica:
  • Europa: 18 CMOS
  • América do Norte: 12 CMOS
  • Ásia-Pacífico: 12 CMOS

Distribuidores globais de saúde

A Sanofi mantém parcerias com 89 redes globais de distribuição de saúde.

Região	Número de distribuidores	Volume anual de distribuição
Europa	32	€ 4,3 bilhões
América do Norte	24	€ 5,1 bilhões
Ásia-Pacífico	33	€ 3,7 bilhões

Empresas de tecnologia e saúde digital

A Sanofi colabora com 56 parceiros de tecnologia e saúde digital.

• Investimento em parceria digital: 780 milhões de euros em 2024
• Principais áreas de foco em tecnologia:
  • Descoberta de medicamentos orientada pela IA
  • Plataformas de telemedicina
  • Monitoramento remoto de pacientes

Centros Médicos Acadêmicos para Ensaios Clínicos

A Sanofi realiza ensaios clínicos com 94 centros médicos acadêmicos em todo o mundo.

Região	Número de centros	Ensaios clínicos ativos
América do Norte	38	62
Europa	36	48
Ásia-Pacífico	20	31

Sanofi (SNY) - Modelo de negócios: Atividades -chave

Pesquisa e Desenvolvimento Farmacêutico

A Sanofi investiu 6,4 bilhões de euros em P&D em 2022. A pesquisa se concentra em várias áreas terapêuticas, incluindo:

• Doenças raras
• Oncologia
• Imunologia
• Neurologia
• Vacinas

Métrica de P&D	2022 Valor
Despesas totais de P&D	6,4 bilhões de euros
Pessoal de P&D	17.000 funcionários
Projetos de pesquisa ativa	120+ projetos

Fabricação e produção de medicamentos

A Sanofi opera 90 locais de fabricação globalmente em 30 países. A capacidade de produção inclui:

• Produção de vacinas: 1,6 bilhão de doses anualmente
• Fabricação farmacêutica: várias categorias terapêuticas

Métrica de fabricação	2022 dados
Locais de fabricação totais	90 sites
Países com fabricação	30 países
Produção anual de vacinas	1,6 bilhão de doses

Marketing global e vendas de produtos médicos

A presença comercial global da Sanofi abrange mais de 100 países com receita de vendas de € 37,8 bilhões em 2022.

Métrica de vendas	2022 Valor
Receita total de vendas	€ 37,8 bilhões
Presença global do mercado	Mais de 100 países

Ensaios clínicos e testes médicos

Sanofi realiza extensa pesquisa clínica com:

• 150+ ensaios clínicos em andamento
• Mais de 25.000 pacientes inscritos em estudos
• Ensaios clínicos de múltiplos fase I-IV

Soluções de Inovação em Saúde e Saúde Digital

Os investimentos em saúde digital se concentram em:

• Descoberta de medicamentos orientada pela IA
• Plataformas terapêuticas digitais
• Tecnologias de medicina personalizadas

Métrica de inovação	2022 dados
Investimentos em saúde digital	€ 500 milhões
Projetos de pesquisa de IA	Mais de 40 iniciativas

Sanofi (SNY) - Modelo de negócios: Recursos -chave

Extensas instalações de pesquisa farmacêutica

A Sanofi opera vários centros de pesquisa em todo o mundo, com um investimento total de pesquisa e desenvolvimento de 6,4 bilhões de euros em 2022. Os principais locais de pesquisa incluem:

Localização	Foco na pesquisa	Funcionários
Paris, França	Sede global de P&D	1.700 pesquisadores
Cambridge, MA, EUA	Pesquisa de doenças raras	800 pesquisadores
Frankfurt, Alemanha	Pesquisa de imunologia	500 pesquisadores

Força de trabalho científica e médica qualificada

A Sanofi emprega um total de 100.787 funcionários em todo o mundo a partir de 2022, com a principal distribuição da força de trabalho:

• Pesquisa e desenvolvimento: 17% da força de trabalho total
• Fabricação: 25% da força de trabalho total
• Vendas e marketing: 30% da força de trabalho total
• Funções administrativas e de suporte: 28% da força de trabalho total

Portfólio de propriedade intelectual robusta

Os ativos de propriedade intelectual de Sanofi incluem:

Categoria IP	Número
Total de famílias de patentes	4,500+
Patentes ativas	2,800
Pedidos de patente arquivados em 2022	350

Infraestrutura avançada de fabricação

A Sanofi opera 45 locais de fabricação globalmente, com recursos de produção em várias áreas terapêuticas:

• Vacinas: 12 locais de fabricação dedicados
• Farmacêuticos: 22 instalações de fabricação
• Cuidados de saúde do consumidor: 6 locais de produção
• Medicamentos de doenças raras: 5 centros de fabricação especializados

Redes de distribuição global

As capas de infraestrutura de distribuição de Sanofi:

Região	Presença de mercado	Centros de distribuição
Europa	Mercado primário	15 centros de distribuição
América do Norte	Mercado estratégico -chave	12 centros de distribuição
Ásia-Pacífico	Região de alto crescimento	8 centros de distribuição
América latina	Mercado emergente	6 centros de distribuição

Sanofi (SNY) - Modelo de negócios: proposições de valor

Soluções de farmacêutica e vacina inovadoras

Em 2023, a Sanofi investiu 6,4 bilhões de euros em pesquisa e desenvolvimento. A portfólio de vacinas gerou € 7,1 bilhões em receita, com as vendas de vacinas covid-19 atingindo 4,3 bilhões de euros.

Categoria de vacina	2023 Receita
Vacinas contra influenza	2,8 bilhões de euros
Vacinas pediátricas	2,5 bilhões de euros
Viagens e vacinas endêmicas	€ 1,8 bilhão

Gama abrangente de produtos de saúde

A Sanofi opera em várias áreas terapêuticas com presença significativa no mercado.

• Cuidado com diabetes: receita de 4,2 bilhões de euros
• Doenças raras: receita de € 3,9 bilhões
• Oncologia: receita de 2,7 bilhões de euros
• Imunologia: receita de € 2,5 bilhões
• Neurologia: receita de 1,8 bilhão de euros

Tratamentos avançados para doenças crônicas e raras

Tratamentos de doenças raras representadas 12.5% da receita farmacêutica total em 2023, totalizando € 3,9 bilhões.

Tratamento de doenças raras	2023 participação de mercado
Distúrbios do sangue raros	€ 1,6 bilhão
Distúrbios de armazenamento lisossômicos	€ 1,2 bilhão
Condições neurológicas genéticas	€ 1,1 bilhão

Tecnologias médicas centradas no paciente

Os investimentos em saúde digital atingiram € 450 milhões em 2023, com foco em plataformas de medicina personalizadas.

• Soluções terapêuticas digitais: € 250 milhões
• Tecnologias de Medicina de Precisão: € 200 milhões

Produtos de saúde de alta qualidade e validados cientificamente

Sanofi mantido 98.7% Conformidade da qualidade do produto em instalações de fabricação global em 2023.

Métrica da qualidade do produto	2023 desempenho
Taxa de conformidade regulatória	98.7%
Consistência de fabricação	99.2%
Taxa de recall de produtos globais	0.3%

Sanofi (SNY) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento profissional médico direto

A Sanofi se envolve com 2,5 milhões de profissionais de saúde globalmente através de canais de comunicação direcionados. A empresa investiu € 178 milhões em assuntos médicos e envolvimento profissional em 2022.

Canal de engajamento	Número de interações	Investimento anual
Conferências médicas	387 eventos internacionais	€ 42,3 milhões
Plataformas profissionais digitais	1,2 milhão de profissionais de saúde registrados	€ 65,7 milhões
Conselhos de consultoria científica	126 painéis de consultoria global	23,5 milhões de euros

Programas de apoio ao paciente

A Sanofi opera programas de apoio ao paciente em 78 países, atendendo a aproximadamente 3,4 milhões de pacientes anualmente.

• Programas de gerenciamento de doenças crônicas
• Iniciativas de assistência financeira
• Suporte de adesão à medicação
• Recursos de educação do paciente

Plataformas de saúde digital e aplicativos móveis

A Sanofi desenvolveu 17 aplicativos de saúde digital com 2,8 milhões de usuários ativos. O investimento em plataforma digital atingiu € 92,6 milhões em 2022.

Plataforma digital	Base de usuários	Área terapêutica
Saúde de Mysanofi	1,1 milhão de usuários	Múltiplas condições crônicas
App de gerenciamento de diabetes	687.000 usuários	Cuidado com diabetes
Rastreador de imunologia	412.000 usuários	Doenças autoimunes

Consultas de saúde personalizadas

A Sanofi fornece serviços de consulta personalizados por meio de 4.200 especialistas em saúde dedicados, atingindo 1,6 milhão de pacientes anualmente.

Educação médica e treinamento em andamento

A empresa investiu € 56,4 milhões em programas de educação médica, apoiando 87.000 profissionais de saúde em todo o mundo em 2022.

Tipo de programa educacional	Participantes	Investimento
Módulos de treinamento on -line	52.000 profissionais	€ 32,1 milhões
Workshops pessoais	23.000 profissionais	€ 15,7 milhões
Programas de colaboração de pesquisa	12.000 profissionais	€ 8,6 milhões

Sanofi (SNY) - Modelo de Negócios: Canais

Distribuidores farmacêuticos

A Sanofi utiliza 72 centros de distribuição globalmente, servindo mais de 170 países. A rede de distribuição farmacêutica da empresa processa aproximadamente 1,2 bilhão de unidades de medicamento anualmente.

Região de distribuição	Número de centros de distribuição	Volume anual de distribuição
Europa	23	380 milhões de unidades
América do Norte	18	290 milhões de unidades
Ásia-Pacífico	15	240 milhões de unidades

Vendas diretas para hospitais e clínicas

A Sanofi mantém uma força de vendas dedicada de 4.800 representantes médicos direcionados diretamente a hospitais e clínicas.

• Duração média das vendas: 12-15 minutos
• Número de instituições de saúde servidas: 62.000
• Receita anual de vendas diretas: 8,4 bilhões de euros

Plataformas médicas online

As plataformas de saúde digital da Sanofi geram 1,2 bilhão de euros em receita de vendas digitais, com 3,7 milhões de profissionais de saúde registrados.

Plataforma digital	Usuários registrados	Receita digital anual
Rede Profissional de Sanofi	2,1 milhões	€ 680 milhões
Portal de informações médicas	1,6 milhão	€ 520 milhões

Redes de varejo farmacêuticas

A Sanofi colabora com 78.000 farmácias em todo o mundo, representando 12,6 bilhões de euros em receita de canal de varejo.

• Cobertura de farmácia: 52 países
• Valor médio da transação de farmácia: € 162
• Integração de prescrição digital: 68% das farmácias parceiras

Conferências médicas e eventos profissionais

A Sanofi participa de 340 conferências médicas anualmente, com um engajamento estimado de 78.000 profissionais de saúde.

Tipo de conferência	Número de eventos	Engajamento profissional
Conferências médicas internacionais	124	42.000 profissionais
Simpósios médicos regionais	216	36.000 profissionais

Sanofi (SNY) - Modelo de negócios: segmentos de clientes

Profissionais de saúde

Em 2023, a Sanofi atendeu a aproximadamente 2,7 milhões de profissionais de saúde em todo o mundo.

Quebra de segmento	Número de profissionais
Médicos	1,8 milhão
Farmacêuticos	650,000
Especialistas	250,000

Hospitais e instituições médicas

A Sanofi se envolveu com 127.500 instituições médicas em todo o mundo em 2023.

• Hospitais públicos: 68.300
• Hospitais particulares: 42.700
• Centros de pesquisa: 16.500

Sistemas de saúde do governo

A Sanofi contratou sistemas de saúde em 84 países, cobrindo aproximadamente 1,3 bilhão de pessoas.

Região	Número de sistemas de saúde do governo
Europa	32
América do Norte	15
Ásia-Pacífico	22
América latina	10
Oriente Médio e África	5

Pacientes individuais com condições crônicas

A Sanofi tem como alvo 87,5 milhões de pacientes com condições crônicas em 2023.

• Pacientes com diabetes: 38,2 milhões
• Pacientes com doenças cardiovasculares: 24,6 milhões
• Pacientes oncológicos: 15,7 milhões
• Pacientes com doenças raras: 9 milhões

Organizações de pesquisa farmacêutica

A Sanofi colaborou com 1.250 organizações de pesquisa globalmente em 2023.

Tipo de organização de pesquisa	Número de colaborações
Instituições acadêmicas	675
Empresas de biotecnologia	350
Centros de Pesquisa Privada	225

Sanofi (SNY) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Em 2022, a Sanofi investiu 6,4 bilhões de euros em despesas de pesquisa e desenvolvimento, representando 14,1% da receita total.

Ano	Despesas de P&D (bilhões de €)	Porcentagem de receita
2022	6.4	14.1%
2021	6.0	13.8%

Custos de fabricação e produção

A rede de fabricação global da Sanofi inclui 90 locais de produção em 30 países.

• Custo dos bens vendidos em 2022: € 22,4 bilhões
• Despesas gerais de fabricação: aproximadamente € 3,5 bilhões

Investimentos globais de marketing e vendas

A Sanofi alocou € 15,2 bilhões para despesas de marketing e vendas em 2022.

Região	Gastos de marketing (milhão de euros)
Europa	5,600
América do Norte	6,800
Resto do mundo	2,800

Despesas de conformidade regulatória

Custos anuais de conformidade regulatória estimados em € 750 milhões.

• Despesas de farmacovigilância: € 180 milhões
• Garantia e controle de qualidade: € 220 milhões
• Arquivamento regulatório e documentação: € 350 milhões

Manutenção de tecnologia e infraestrutura

Investimento de infraestrutura de tecnologia em 2022: € 1,2 bilhão.

Categoria de tecnologia	Despesas (milhões de euros)
Infraestrutura de TI	450
Transformação digital	350
Segurança cibernética	200
Serviços em nuvem	200

Sanofi (SNY) - Modelo de negócios: fluxos de receita

Vendas farmacêuticas de produtos

Em 2022, a receita total de Sanofi atingiu € 42,8 bilhões. As vendas de produtos farmacêuticos contribuíram significativamente para este número.

Categoria de produto	Receita (€ bilhão)
Doenças raras	4.3
Imunologia	3.9
Oncologia	2.7
Neurologia	2.1

Distribuição da vacina

As vendas de vacinas geraram 7,5 bilhões de euros em receita para a Sanofi em 2022.

• Contribuições da vacina covid-19: 2,3 bilhões de euros
• Vendas de vacinas contra influenza: € 1,8 bilhão
• Vacinas pediátricas: € 1,5 bilhão

Licenciamento de tecnologias médicas

Os acordos de licenciamento geraram aproximadamente € 850 milhões em 2022.

Área de tecnologia	Receita de licenciamento (milhão de €)
Biotecnologia	450
Inovações farmacêuticas	250
Tecnologias de pesquisa	150

Contratos de Serviço de Saúde

Os contratos de serviço contribuíram com € 1,2 bilhão para a receita da Sanofi em 2022.

• Serviços de ensaios clínicos: € 500 milhões
• Consultoria médica: € 350 milhões
• Serviços de laboratório: € 350 milhões

Acordos de colaboração de pesquisa

As colaborações de pesquisa geraram € 650 milhões em 2022.

Tipo de colaboração	Receita (milhão de €)
Parcerias acadêmicas	250
Parcerias farmacêuticas	300
Colaborações de biotecnologia	100

Sanofi (SNY) - Canvas Business Model: Value Propositions

First- and best-in-class medicines for complex diseases like atopic dermatitis and COPD.

Dupixent, addressing atopic dermatitis, asthma, and chronic obstructive pulmonary disease (COPD), generated quarterly global sales of €4.2 billion in the third quarter of 2025, surpassing the €4 billion milestone for the first time in a single quarter. US sales for Dupixent in Q3 2025 rose by 27.9%. For the first half of 2025, Dupixent sales reached €7.312 billion.

The drug's approvals now include its eighth indication, bullous pemphigoid, in June 2025 in the United States.

Indication/Metric	Time Period	Value/Amount
Dupixent Quarterly Sales	Q3 2025	€4.2 billion
Dupixent Sales Growth (Y/Y)	Q3 2025	26.2%
Dupixent US Sales Growth (Y/Y)	Q3 2025	27.9%
Dupixent Half-Year Sales	H1 2025	€7.312 billion

Innovative vaccines for infectious disease prevention, exemplified by Beyfortus (nirsevimab).

Sanofi's total vaccine sales in Q3 2025 were €3.4 billion. In the second quarter of 2025, total vaccine sales increased by 10.3% to €1.214 billion. Beyfortus sales in Q2 2025 were €72 million, representing a year-over-year increase of 322.2%. For the first half of 2025, Beyfortus sales reached €356 million, growing 79.0%. The vaccine generated €1.7 billion in worldwide sales in 2024.

Targeted therapies for rare diseases, bolstered by the Blueprint Medicines acquisition.

Overall pharmaceutical launches, which include rare disease treatments like Ayvakit and ALTUVIIIO, increased sales by 57.1% to reach €1.0 billion in Q3 2025. ALTUVIIIO, for hemophilia A, recorded Q3 2025 sales of €294 million, up 81.4% year-over-year. For H1 2025, ALTUVIIIO sales were €542 million, a growth of 95.4%. Qfitlia, approved in March 2025, generated $1 million in revenue within its first three months.

Sanofi has 94 projects in its pipeline across four main disease areas and Vaccines as of Q3 2025.

Commitment to patient-centric solutions and accessibility programs.

Sanofi US expanded its Insulins Valyou Savings Program in September 2025 to offer any Sanofi insulin for a fixed monthly price of $35 to all patients in the US with a valid prescription. The company's Global Health Unit has provided treatments for non-communicable diseases to one million patients since 2021.

• Advocates from more than 140 US organizations have participated in Sanofi's Patient Advocacy Community of Practice.
• The Sanofi Global Workplace Accessibility Standards include 209 criteria.
• In 2024, 78% of respondents found Sanofi doing well or extremely well on identifying and addressing unmet patient needs.

Sanofi (SNY) - Canvas Business Model: Customer Relationships

You're looking at how Sanofi (SNY) builds and maintains connections with the people who use and influence its medicines, which is critical given the complexity of specialty care. Honestly, the relationship strategy is heavily weighted toward high-touch support and digital enablement, especially where adherence is a known challenge.

Dedicated medical science liaisons (MSLs) for high-touch engagement with specialists.

The presence of roles like the Kuznetsov Evgeniy, Scientist at Sanofi MSAT laboratory in Waterford, Ireland, and a listed MSL Manager for Eurasia MCO at a November 2025 event, confirms the structure for dedicated, high-level scientific engagement with healthcare professionals (HCPs). This relationship channel is key for complex, specialty-care products. The financial success of these relationships is evident in the performance of key launches; for instance, Pharma launches reached sales of €0.8 billion in Q1 2025, up 43.8%.

Patient support programs for complex, specialty-care treatments.

Sanofi (SNY) directly addresses the adherence gap, as studies show only about 50% of patients with chronic conditions regularly take their medications as prescribed. To combat this, their patient support programs are actively recognized. For example, the Sanofi/Regeneron support for Dupixent shared first place in the 2025 PURE Awards for Dermatology and won in Respiratory. The PURE Engagement assessment in 2025 gathered over 10,000 ratings across more than 50 pharmaceutical manufacturers to determine these benchmarks. For markets outside the US and China, Sanofi utilizes a paid Named Patient Program to ensure treatment delivery.

Long-term, institutional relationships with major hospital systems and payers.

These relationships are foundational to market access and reimbursement, though specific contract values aren't public. The financial results reflect the strength of these institutional ties. For the first half of 2025, Sanofi's Net Sales totaled €19,889 million, with US sales alone reaching €4,878 million in H1 2025. Furthermore, the company's Business Operating Income (BOI) for H1 2025 was €5,363 million. The commitment to resilience in healthcare systems is part of their updated sustainability strategy.

Digital health tools for patient adherence and disease management.

Sanofi is building out its digital platform to engage patients directly, aiming to be a leading digital healthcare platform for providers, payers, and patients. They have an expanded multi-year partnership with BrightInsight to deploy regulated digital health companion applications, including the 'MyWay' mobile application for symptom tracking and medication management in select countries. This digital push is necessary because in certain developed countries like the US and Canada, up to 70% of patients can be lost during the journey due to administrative burdens or lack of support before treatment fully takes hold. The company is actively scaling these solutions, adding 50 new diseases to these programs every year. A pilot study involving 100 diabetes patients using the H2S Sanofi digital solution showed improved medication adherence and reduced hospitalizations.

Here's a quick look at the scale of the business supporting these relationships as of H1 2025:

Metric	Value (H1 2025)	Context
Net Sales	€19,889 million	Total revenue for the first half of 2025
Dupixent Sales	€3.5 billion	Sales for Q1 2025, a key specialty-care driver
Digital Pilot Patients	100	Patients in a diabetes monitoring study using a Sanofi digital solution
New Digital Diseases Added Annually	50	Number of new diseases being integrated into AI-powered patient engagement platforms
Patient Adherence Baseline	~50%	Approximate percentage of chronic condition patients taking medication as prescribed

You should definitely review the impact of the BrightInsight partnership on patient onboarding time versus the 70% drop-off rate mentioned in complex markets.

Sanofi (SNY) - Canvas Business Model: Channels

You're looking at how Sanofi (SNY) gets its products-from routine flu shots to complex biologics-into the hands of patients and providers as of late 2025. The channel strategy is a mix of broad-reach logistics and highly targeted specialty engagement.

Global network of pharmaceutical wholesalers and distributors

Sanofi relies heavily on the established, large-scale infrastructure of pharmaceutical wholesalers and specialty distributors to move the bulk of its prescription volume. This channel is critical for ensuring broad market access across hospitals, retail pharmacies, and physician offices for many of its established and newly launched products. While specific Sanofi-tied distribution volume percentages aren't public, the overall U.S. pharmaceutical distribution industry, which Sanofi taps into, is characterized by the vertical integration and broad reach of the Big Three distributors.

The company's geographic sales performance reflects this broad reach. For instance, in the first half of 2025 (H1 2025), U.S. sales reached €4,878 million, while Europe accounted for €2,101 million, showing the scale required through these partners.

Direct sales force targeting specialty physicians and key opinion leaders (KOLs)

For high-value, complex, or newly launched therapies, Sanofi deploys a specialized direct sales force. This team focuses on deep engagement with specialty physicians and Key Opinion Leaders (KOLs) to drive adoption based on clinical data. This targeted approach is essential for products in their initial launch phase or those requiring specialized prescribing knowledge. The success of this channel is evident in the performance of key launches. For example, the immunology blockbuster Dupixent generated €3.8 billion in sales in the second quarter of 2025 alone. Also, newer launches, including the hemophilia medication Altuviiio, which saw Q2 2025 sales of €291 million, are heavily reliant on this direct, specialized detailing effort.

The company's overall focus on innovation is supported by a significant commercial allocation; SG&A (Selling, General, and Administrative expenses) increased at half the rate of sales growth in Q2 2025, with 70% of that increase allocated to sales and marketing for current and future launches.

Specialty pharmacies for high-cost biologic and rare disease treatments

High-cost biologics and rare disease treatments, like those acquired through the Blueprint Medicines buyout (e.g., Ayvakit for systemic mastocytosis), often require limited distribution networks managed through specialty pharmacies. These pharmacies handle complex logistics, patient support programs, and reimbursement navigation. This channel ensures that patients with rare conditions receive their specialized medication correctly. The focus on rare diseases is a strategic priority, with Sanofi Ventures commitment reaching over $1.4 billion in assets under management to support pipeline replenishment in these areas.

Government health departments for vaccine procurement and distribution

Vaccines are a major component of Sanofi's channel strategy, involving large-scale procurement and distribution agreements with government health departments globally. This channel is characterized by high volume and seasonal demand fluctuations. For the third quarter of 2025 (July to September), Sanofi's overall vaccine sales were €3.4 billion. However, the flu and COVID-19 vaccine segment faced headwinds, with sales decreasing by 16.8% to €1.5 billion for that quarter, partly due to lower immunization rates in the U.S.. Conversely, the newer RSV preventive drug, Beyfortus, showed strong uptake, achieving €739 million in Q3 2025 sales, driven by rollouts across 40 countries.

Here's a look at how key product sales map against the geographic regions that rely on these channels in H1 2025:

Geographic Channel Segment	H1 2025 Sales (€ million)	Q3 2025 Sales (€ million)	Key Channel Driver Context
United States (Primary Direct/Specialty/Wholesale)	4,878	3,073	Vaccine uptake pressure noted in Q3
Europe (Primary Wholesale/Direct)	2,101	504	Price competition noted in Germany for vaccines
Rest of World (Mixed Channels)	3,015	579	Growth led by Vaccines (e.g., Beyfortus rollout)
Total Vaccines (Legacy Flu/COVID-19) Q3 2025	N/A	1,530	Represents sales through all channels for these specific products

The company is also actively managing its capital structure, which impacts its financial flexibility to support these channels, having completed 80.3% of its planned €5 billion share buyback program for 2025.

You should review the Q4 2025 earnings release to see the final impact of the late-year flu season on the government procurement channel.

Sanofi (SNY) - Canvas Business Model: Customer Segments

You're looking at the core groups Sanofi (SNY) serves to drive its business, which is heavily weighted toward specialty care and vaccines as of late 2025. Honestly, the numbers show where the real focus is right now.

Patients with Type 2 inflammatory diseases (e.g., asthma, atopic dermatitis, COPD).

This group is central, largely driven by the success of Dupixent. Dupixent sales hit a quarterly record of €4.2 billion in the third quarter of 2025, following €3.8 billion in the second quarter of 2025. Globally, more than 1,000,000 patients are currently being treated with Dupixent across its approved indications as of September 2025. For asthma alone, data suggests 50% to 70% of adult patients have Type 2 Inflammation.

• Dupixent US sales in Q3 2025 exceeded €3 billion for the first time in a quarter.
• The drug is approved in more than 60 countries across multiple indications.

Healthcare providers (HCPs) and specialists (e.g., pulmonologists, dermatologists).

Sanofi (SNY) engages HCPs by presenting data at major medical congresses, reinforcing their role as key decision-makers for prescribing specialty treatments. For instance, data on Dupixent in COPD and amlitelimab in asthma were featured at the European Respiratory Society (ERS) International Congress in September 2025. Furthermore, new data supporting therapies like WAYRILZ for immune thrombocytopenia (ITP) were presented at the American Society of Hematology (ASH) Annual Meeting in November 2025.

Government and public health agencies for flu and pediatric vaccines.

This segment is critical for the Vaccines business unit, though subject to seasonal and competitive pressures. Total vaccine sales in Q2 2025 increased by 10.3% to €1.21 billion, partly due to the rollout of Beyfortus. However, Q3 2025 saw overall vaccine sales decline by 7.8% to €3.4 billion, largely attributed to a slowdown in influenza shots. Sanofi Pasteur Inc. also received a contract from the Department of State in April 2025 for $22,259.

The company actively targets these agencies with evidence on public health impact, such as a study in Spain demonstrating the positive environmental impact of the all-infant 2023-2024 immunization program against RSV with Beyfortus.

Patients with rare diseases (e.g., systemic mastocytosis, Pompe disease).

Sanofi (SNY) has a deep foundation here, focusing on lysosomal storage disorders (LSDs) and other rare conditions. The company is actively expanding this portfolio, notably through the acquisition of Blueprint Medicines, which brought in Ayvakit for systemic mastocytosis. Sales for Nexviazyme/Nexviadzyme were €192 million in Q2 2025. The company notes there are around 7,000 to 9,000 known rare diseases globally.

The digital engagement with this segment is also measurable; Sanofi has globally one and a half million patients on record across its rare disease digital tools as of mid-2025.

Rare Disease Product/Area	Relevant Financial/Statistical Data (Late 2025)	Patient/Market Context
Nexviazyme/Nexviadzyme (Pompe)	Sales: €192 million (Q2 2025)	Driven by patient switches from Myozyme (sales down 19.4% to €140 million in Q2 2025)
Altuviiio (Hemophilia A)	Sales: €230 million (Q4 2024)	More than 85% of sales were in the United States
Ayvakit (Systemic Mastocytosis)	Acquisition value of Blueprint Medicines: approx. $9.1 billion	Strengthens position in rare immunology diseases

Managed care organizations and national payers determining formulary access.

Access and reimbursement decisions by payers and Pharmacy Benefit Managers (PBMs) are a key hurdle for Sanofi (SNY) products. In May 2025, Sanofi US received a subpoena from the HHS-OIG seeking information about its agreements with PBMs and group purchasing organizations (GPOs). The company's focus on value-based care is evident in its ongoing analysis, such as through its 'Managed Care Digest Series,' which analyzes trends in chronic disease management and health plan models.

The financial impact of payer dynamics is reflected in the gross-to-net adjustments that affect reported sales, though the company is focused on profitable growth, with Business Net Income up 7.6% in H1 2025.

• Sanofi intends to complete a €5 billion share buyback program in 2025, with 86.1% executed as of October 2025.
• Business EPS guidance for 2025 is confirmed at a low double-digit percentage growth at constant exchange rates (before buyback).

Sanofi (SNY) - Canvas Business Model: Cost Structure

You're looking at the major cash outlays that fuel Sanofi's engine, which is heavily weighted toward future innovation. Honestly, the cost structure reflects a company doubling down on its R&D-driven transformation, which means big upfront spending now for potential blockbuster returns later.

The most immediate, recurring cost pressure point you see in the mid-2025 reporting is Research and Development (R&D). This isn't just maintenance spending; it's the fuel for their next wave of growth, especially following major acquisitions. For instance, R&D expenses in the second quarter of 2025 hit €1.9 billion, representing a significant 17.7% year-over-year increase. That acceleration is key to note.

Operating expenses also reflect the commercial push behind new products. Selling, General, and Administrative (SG&A) costs in Q2 2025 were reported at €2.3 billion, which was an increase of 7.8%. This category absorbs the costs of global product launches, like supporting the rollout of Dupixent for Chronic Obstructive Pulmonary Disease (COPD) and scaling up the commercial footprint for other recent launches.

Then you have the capital allocation for future capacity, which is a massive, multi-year commitment. Sanofi has publicly committed to investing at least $20 billion in the United States through 2030. This isn't an annual expense, but a strategic outlay where billions are earmarked specifically for expanding domestic manufacturing capacity-a direct cost related to complex biologics production and supply chain resilience-alongside increased R&D spending in the U.S..

To round out the major financial commitments, you have the inorganic growth costs. The acquisition of Blueprint Medicines Corporation, which bolsters their rare disease and immunology portfolio, was a cash outlay valued at approximately $9.1 billion. Including contingent value rights (CVRs) tied to pipeline milestones, the total potential transaction value reached approximately $9.5 billion.

Here's a quick look at some of these major financial figures driving the cost side of the canvas:

Cost Category / Investment	Financial Amount / Metric	Period / Scope
Research & Development (R&D) Expense	€1.9 billion	Q2 2025
R&D Expense Year-over-Year Change	17.7% increase	Q2 2025
Selling, General & Administrative (SG&A) Expense	€2.3 billion	Q2 2025
U.S. Strategic Investment Commitment	At least $20 billion	Through 2030
Blueprint Medicines Acquisition (Upfront Cash)	$9.1 billion	Completed in 2025
Blueprint Medicines Acquisition (Total Potential Value)	Approximately $9.5 billion	Including CVRs

The manufacturing aspect, especially for complex biologics, is embedded within the U.S. investment plan, which includes allocating billions of dollars to expand domestic manufacturing sites and partnerships. You can see the cost structure is heavily tilted toward future revenue generation, which is a calculated risk, but one they're funding with strong current sales from key assets like Dupixent, which hit €3.8 billion in sales in Q2 2025.

The costs associated with maintaining a competitive pipeline involve several moving parts:

• Accelerating R&D spending in the U.S. as part of the $20 billion plan.
• Integrating acquired assets like Blueprint Medicines, which brings in costs related to the acquired product Ayvakit/Ayvakyt and its pipeline.
• Covering the development cost share for Dupixent, which is expected to result in a negative Business Operating Income (BOI) impact of approximately €300 million in 2026 and €800 million in 2027 from the partner reimbursement schedule.
• General operational expenses supporting nine newly launched medicines and vaccines, which drove 47.3% growth in launch sales in H1 2025.

Finance: draft 13-week cash view by Friday, focusing on the impact of the Blueprint integration on near-term cash flow.

Sanofi (SNY) - Canvas Business Model: Revenue Streams

You're looking at the hard numbers driving Sanofi's top line as of late 2025. The revenue streams are clearly anchored in their specialty care portfolio, supported by a growing vaccines segment and recent product introductions.

The overall expectation for the full fiscal year 2025 is for sales to grow by a high single-digit percentage at constant exchange rate (CER).

Here's a breakdown of the key revenue drivers based on the second quarter of 2025 performance:

Revenue Stream Component	Q2 2025 Sales Amount (€ million)	Year-over-Year Growth (CER)	Contextual Data Point
Total Net Sales	9,994	10.1%	Total Q2 2025 Sales
Specialty Care (Dupixent)	3,800	21.1%	Driven by growth across all approved indications, including the COPD launch.
Vaccines (Total)	1,214	10.3%	Aided by the geographic rollout of Beyfortus.
New Product Launches (Aggregate)	900	39.8%	These nine recent launches now account for 10% of total sales.
Influenza Vaccines	141	26.1%	Reflecting one-offs from late-season immunizations in the US and Europe.
Beyfortus Sales	72	N/A	Through expansion of infant protection in Rest of World, including Japan.

The specialty care segment remains the powerhouse, but the success of the newer portfolio is significant:

• Sales from the nine newly launched medicines and vaccines grew by 47.3% in the first half of 2025.
• The new product launches contributed €0.9 billion in Q2 2025 sales.

Revenue from co-developed products involves both income and profit-sharing arrangements. For instance, in Q2 2025, income included €61 million from license-out royalties and other capital gains. However, this was partially offset by the expense representing the partner's share of profit from the monoclonal antibody alliance, which was €1,265 million in Q2 2025.

Looking at the year-to-date performance for licensing income, Q3 2025 reported license-out royalties, etc., of €144 million, which included €69 million on Amvuttra® for that quarter alone.